All Articles

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

Toronto's Kepler Communications is betting big on optical links and on-orbit computing. A new deal with Rocket Lab signals a major escalation in the race to control space data.

Getty Images faces a liquidity crisis with soaring debt and a failed merger, raising doubts about its future despite some growth in its core business.

Sumisho Air Lease reports a 98% profit drop in its first post-acquisition quarter, but accounting shifts mask a deeper strategic realignment for the lessor.

BODi posts a fourth straight profitable quarter, but with revenue and subscribers in freefall, is its dramatic cost-cutting a sign of health or stagnation?

Amidst declining revenue and layoffs, Rapid7's new CEO is making a bold bet on a focused, AI-driven strategy. Is this the path to renewed strength?

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

P3 Health Partners stuns Wall Street with a swing to profitability, but a deeper dive reveals one-time gains and a strategic pivot. Is this the new playbook?

Entravision's ad-tech unit soared 230% on AI, driving record profit. But with its legacy media arm in decline, can this tech pivot redefine its future?

Insight Molecular Diagnostics has key regulatory and reimbursement wins for its game-changing transplant test, but a high cash burn creates a high-stakes race to commercialization.

In a blockbuster deal with Boeing, Archer acquires key assets to build a 'physical AI' powerhouse. But with soaring losses, is it a masterstroke or a costly bet?

Tactile Medical's impressive Q2 profit growth is tempered by a product launch stumble, testing its execution as it places big bets on new markets and tech.

Alico's Q3 results reveal a successful pivot from citrus giant to land developer, with profits soaring and major projects advancing. How is this changing Florida?

Metagenomi Therapeutics is on track for a pivotal 2027 clinical trial, but its advanced gene editing tech faces a market wary of high-cost cures.

Angie O'Leary's promotion at Commercial Vehicle Group is more than a new title. It's a strategic bet on continuity to navigate a turbulent EV transition.

Facing a 50% revenue collapse and mounting losses, The Arena Group is rebranding to Paradium.AI, a high-stakes pivot to save itself with technology.

Fluent's Q2 results reveal a dramatic pivot, with Commerce Media Solutions booming 90%. But can this growth and a new in-store bet outrun a stark 'going concern' warning?

Shimmick Corp. posts improving financials and a record backlog, but a closer look reveals the high cost of its strategic pivot from troubled legacy projects.

Beyond the hype of AI models and drones, Kopin is building the critical optical networks and displays that make them possible. A look at its strategic Q2.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.